CAR-T cell therapy for autoimmune diseases
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a treatment called CNCT19, a type of CAR-T cell therapy, for people with certain autoimmune diseases like neuromyelitis optica, myasthenia gravis, or multiple sclerosis that have come back or not responded to other treatments. It aims to see if targeting a specific immune cell (CD19) can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a diagnosis of one of these conditions: neuromyelitis optica, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, autoimmune encephalitis, or MOG antibody disease.
- Your disease has come back or not responded to at least one or two standard treatments.
- You have a certain level of disability (like walking, muscle weakness, or daily function) per your condition.
- Your organ function (blood, liver, kidneys, heart, lungs) is within acceptable limits.
- You are not pregnant, breastfeeding, and agree to use birth control during the study and for 24 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new CAR-T cell therapy called HY001N for people with hard-to-treat neurological autoimmune diseases like NMOSD, myasthenia gravis, MS, and others. It aims to see if targeting B cells can help when standard treatments have failed.
This trial tests a universal CAR-T cell treatment for people with autoimmune diseases of the nervous system that haven't responded to standard therapies. It aims to see if this therapy can help control diseases like neuromyelitis optica, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multiple sclerosis.
This early-stage trial tests a new type of immune cell therapy (CAR T-cells) against several relapsed or hard-to-treat autoimmune diseases that affect the nervous system. The goal is to see if this treatment can safely calm the immune system and improve symptoms.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests whether CAR-T cells, a type of immune cell therapy, can help people with certain autoimmune diseases. If you have lupus, scleroderma, or other listed conditions, you may be able to join and see if this treatment can calm your overactive immune system.
This trial tests whether a type of immune cell therapy called CAR-T cells can help treat autoimmune diseases. It is for people who have not tried this type of therapy before.
Hear when a new Neurological Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.